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The human ct,-adrenergic receptor contains the sequence KASRWRGRQNREKRFTF (amino acids 356-372) at the C-terminal end of its third 
intracellular loop. This sequence satisfies the structural criteria for G protein-activating sequences [(1992) J. Biol. Chem. 267, 8342-8346] except 
that he C-terminal sequence is B-B-X-X-Phc instead of B-B-X-B or B-B-X-X-B (B: basic residue, X: non-basic residue). Nevertheless, the synthetic 
pgptidc orresponding to this sequence (peptide cz2-F) was found to activate G~ and Go strongly with a saturated lTeet at 1-3 #M. Furtherntore, 
the substitution fthe C-terminal Phe of peptide ~:-F with Are. Trp, and Tyr (but not Ala or Asp) did not appreciably affect he O:activating 
potency. It is suggested that he C.terminal basic residue of the B-B-X-X-B motif in G:activating sequences can be replaced by an aromatic residue. 
~:-Adrenergic receptor; G:eoupling mechanism; G:activator sequence; G protein-activator sequen¢~ motif; Aromatic amino acid 
1. INTRODUCTION 
Horanones, neurotransmitters, growth factors, and 
eytokines initiate the cytoplasmic signals by binding to 
their own receptors on the cell surface. Some of the 
receptors exert their function by activating intracellular 
effectors, such as enzymes and ion channels, via the 
intermediary role of GTP-binding G proteins [1]. 
Among these G-coupled receptors, there are at least 
seven types of adrenergic receptors, which mediate the 
effect of epinephrine and norepinephrine. The 0qAR 
(~.~-adrenergic receptor) belongs to this family, the func- 
tion of which is mainly mediated by G~ activation [2]. 
Sequence analysis predicts that most of the G-cou- 
pled receptors consist of the membrane-spanning struc- 
ture with seven transmembrane domains, which forms 
three cytoplasmic loops and one C-terminal tail [2]. The 
mutagenesis studies of the receptor~G protein pairs, 
flAR (/3-adrenergic receptor)-G~ [3-6], rhodopsin-Gt [7- 
10], and mAChR (muscarinie acetylcholine r eeptor)-G~ 
[11], have specified short regions in the receptors that 
are required for interaction with G proteins. In particu- 
lar, the C-terminal portions of I3 (the third intraeellular 
loop) of G-coupled receptors have been proposed to be 
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the most likely region involved ila G protein coupling. 
However, it remained undetermined whether this is tile 
case with 0~_,AR. 
Our previous study [12-14] clarified that IGF-IIR 
(in~ulin-like growth factor 1I receptor) interacts with 
and activates Gi in an environment of phospholipid 
vesicles as well as in that of native BALB/c 3T3 cell 
membranes. The mode of their interaction was found to 
be the same as that between conventional G-coupled 
receptors and G proteins, despite the fact that IGF-IIR 
is a receptor with a single transmembrane domain. We 
subsequently found that the Arg-~ata--Lys ~'-3 sequence of 
IGF-1!R can activate Gi directly in the same manner as 
conventional G-coupled receptors [15,16]. Notably, the 
function of this sequence was found to depend entirely 
upon the presence of: (i) at least two basic residues at 
the N-terminal side and (it) the sequence B-B-X-B or 
B-B-X-X-B (where B is a basic residue, and X is a 
non-basic residue) at the C-terminus. Therefore, it is 
reasonable to assume that G-coupled receptors contain 
G protein-activator sequences that satisfy (i) and (it) in 
addition to (iii) 10 ~ residue length ~ 26. Based on these 
criteria, we have identified a G:activator egion in the 
C-terminal end of la of flzAR and a GJOo-aCtivator 
region in the comparable portion of M4AChR (M4 sub- 
type mAChR) [17]. Furthermore, ~.~AR was found to 
possess a G:activator egion in its second intracellular 
loop and a region in the N-terminal end of 13 that acti- 
vates all of G~, Go, and G~ non-selectively. The former 
fact is consistent with the study indicating that ~2AR 
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activates G, in response to high concentrations of the 
~ca-adrenergic agonists [18,19]. 
Based on the criteria (i)-(iii), on the other hand, it was 
impossible to find regions in czAR that can specifically 
activate Gi, a G protein to which this receptor is coupled 
in native conditions. The C-terminal end of I~ of ~2AR 
had consisted of a sequence quite different from that 
satisfying these criteria [17,20]. Recently, the sequence 
of ¢z.,AR has been partially corrected [21], which gave 
rise to the sequence similar to the sequence that satisfies 
(i)-(iii). It is KASRWRGRQNREKRFTF  located in its 
C-terminal end of I3~ which satisfies (i) and (iii), but has 
a B-B-X-X-F structure at its C-terminus. A Phe residue 
is substituted for the extreme C-terminal basic residue. 
This study was conducted to find a specific G~-activator 
region in ;¢.~AR and to see whether or not other residues 
can be substituted for its extreme C-terminal residue. 
2. EXPERIMENTAL 
2.1. G'I"P~'S bindhzg assay 
GTP?'S binding to G proteins was assayed at 37°C in the presence 
of 20,aM MS 2. and 60 nM [35S]GTPTS (GTPTS, guanosine-5'-o-(3- 
thiotriphosphate)), asdescribed previously [15]. G'FPTS binding to 
polypeptide was negligible. The total amount of O proteins 'was meas- 
ured as maximal GTP?'S binding at room temperature, asdescribed 
[22]. [~S]GTPT$ was purchased from Du Pont-New England Nuclear. 
Binding of GTPTS to G proteins obeyed the first-order kinetics ac- 
cordins to the equation ln[(Br-B)/litr]=-k,~t , where B is the binding 
at time t and BT is the total binding observable at an infinite time. 
Thus, the apparent first-order rate constant for GTP?S binding (k.~,p), 
which is equal to the slope ofthe tangent to the GTPTS-hinding curve 
at time 0 and represents he actual GTPTS binding rate, was calculated 
from this equation and the value of B at 2 rain for Go, ~ rain for G~ 
and 10 rain for O,. 
2.2. Materials 
The receptor polypeptides used in this study were synthesized by the 
solid phase method and purified to near homogeneity by high-per- 
formance liquid chromatography, as described [15]. The lyophilized 
synthetic polypeptides were dissolved in distilled water. G~ and Go, 
which wcr¢ purified from bovine brain to homogeneity, were provided 
by Dr. Toshiaki Katada (Tokyo Institute of Technology, Yokohama, 
Jspan) [23]. The Gi used in this study was trimeric GL,.. G,=, was purified 
from Sf9 cells transfected with (is.encoding baculovirus as described 
[24] with slight modifications using Mono Q column chromatography. 
3. RESULTS AND DISCUSSION 
We tested the ability of KASRWRGRQNREK-  
RFTF,  which is located at residues 356-372 of ~z.~AR, 
to activate G~. This polypeptide was referred to as pep- 
tide ~2-F. Peptide cx2-F activated G~ as assessed by deter- 
mining the rate constant value, k~pp, of GTPTS binding 
(Fig. 1). The action of peptide ~,-F reached saturation 
at 1-3 pM of this peptide with an EC~0 of ==300 riM. 
This sequence is one of the receptor sequences that are 
the most potent in activation of O~. A sequence ::,ith 
similar potency of the activity was reported in 
M~AChR, another native Grcoupled receptor [17]. It is 
RNQVRKKRQMAARERKYTR,  which has a C-ter- 
minal structure very similar to the present sequence. 
To clarify the G protein specificity, we examined the 
dose-response r lationship for the action of peptide ~z,.- 
F on each of Oi, Go and G~. As shown in Fig. 2, peptide 
;c2-F activated Go with larger et'ficacy and less potency. 
The efficacy of the peptide action on Go was == 1.3-fold 
of its Gractivating ability. The ECs0 value of the peptide 
action on Go was estimated to be 500 riM, which is 
significantly higher than the ECso value, 300 nM, of its 
G~-activating ability. In contrast, this peptid¢ indicated 
a weak action on G~ with smaller efficacy and lower 
potency. The efficacy of the peptide action on G~ was 
==2/3 of its Gractivating ability and ==1/2 of its Go- 
activating activity. The EC~0 was estimated to be 1 ,aM. 
This suggests that the peptide ¢xz-F sequence isa G~/Go- 
activator egion of 0bAR. It has been reported [25] that 
purified ~z~.AR couples to Go as potently as to G~ in 
phospholipid vesicles, which is consistent with the pres- 
ent study. It was also reported that the C-terminal Mi l l  
region of 13 of M4AChR possesses a potent activity to 
activate Go as well as Gi [17]. The characteristic that 
G/Go-aCtivator egions are present in the C-terminal 
end of I~ may be commonly shared by Greoupled recep- 
tors with multiple membrane-spanning configuration. 
Next we carried out a series of experiments oaddress 
the question of whether other residues can substitute the 
extreme C-terminal Phe of peptide 0h-F. The Gi-activa- 
tor peptide ~.~-F sequence possesses the B-B-X-X-F 
structure at its C-terminus, whereas G protein-activator 
regions in M~AChR, Fl~AR, and IGF-I IR share the B- 
B-X-B or B-B-X-X-B motif at their C-terminus. Thus, 
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Fig. 1. Effect of peptide ~z~-F on GTPTS binding to various O proteins, 
By incubating O proteins (Gt, m; Go, 'P; O,, m) with peptide ;q-F 
(KASRWRGRQNREKRFTF, residues 356-372 of human ~x=AR), 
GTPTS binding was assayed under the conditions described in section 
2. The GTPTS binding rate was assessed as the rate constant, k pp, and 
the extent or" stimulation was expressed as the degree of stimulation 
of the rate constant relative to the basal fate. The method used for 
calculation is described in section 2. The basal values ofk=vv were 0.070 
_+ 0.001 for G=, 0.177 + 0.022 for Go, and 0.029 :t: 0.005 for G, (min "~, 
mean ;t: S.E.) at these xperiments. 
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FiB. 2. Effect of pcptide ~t:-F variants witl: its extreme C-terminal residue substituted onGTP~,S binding to G~. (A) Effect of Arg substitution, (B) 
effect of aromatic acid substitutions, (C)effect of Ala and Asp substitutions. By incubatin~ Gtwith peptide ff:-R in A (m. peptide g~.-F; ,. pcptide 
a:-R (KASRWRGRQNREKRFT_R)) or peptide ~:-Y and -W; in B (m, peptid¢ a,-F; ¢, peptide ~t.,.Y (KASRWRGRQNREKRFTY); a. pcptide 
~z,.W (KASRWRGRQNREKRFTW)), or peptide ~t,-D and -A; in C (m, peptid¢ z:-F; o. peptide g.,-D (KASRWRGRQNREKRFTD; B, peptid¢ 
<x:-A (KASRWRGRQNREKRFT_A)), GTP~,S binding was assayed under the same conditions as those descril:v~ in the legend for FiB. !. Values 
represent the mean ± S.E. of six experiments. Since the experiments described inA and B were done together, the dose-response curve of peptide 
~2-F as a positive control was the same between A and B, whereas the experiments in C were done ~¢pamtely. The basal values of k+, for 13+ were 
0.071 ± 0.002 in A and B, and 0.069 ± 0.002 il~ C (rain -~. mean + S.E.). 
it is intriguing to examine whether the C-terminal Phe 
can be substituted with other residues, including basic 
residues. As shown in Fig. 2A, the substitution of Arg 
for the C-terminal Ph¢ resulted in almost identical po- 
tency and efficacy of the action on Gi, suggesting that 
basic residues can be substituted for the extreme C- 
terminal Phe without altering the potency of the peptide 
action. 
The Phe residue belongs to an aromatic amino acid 
family, which is apt to bind other residues through hy- 
drophobic binding. Thus, we further examined whether 
aromatic residues Tyr and Trp can be substituted for 
the C-terminal Phe of peptide g:-F without changing the 
G:activating activity. Fig. 2B shows that this is the case. 
When the peptide ~-F  variants, the extreme C-terminal 
residue of which was Tyr or Trp, were synthesized, they 
indicated G:activating activity with a potency similar 
to that of peptide ~x:-F, although their efficacy was 
slightly diminished. In contrast, when Asp was substi- 
tuted for the C-terminal residue, both the potency and 
efficacy of the peptide to activate G~ were markedly 
diminished (Fig. 2C). When Ala was substituted, the 
peptide completely lost its G j-activating function. 
Therefore, it is reasonable to assume that basic residues 
or aromatic ones are allowable as the C-terminal rest. 
due of the Gl-activator egion of g2AR. 
In summary, we localized a potent G/Go-aCtivator 
region of~2AR to residues 356-372. We [21] previously 
reported that this receptor contains a region in the see- 
end intracellular loop that can activate Gs selectively, 
and a region in the N-terminal end of I~ that activates 
plural 13 proteins with low potencies. Thus. it is likely 
that ;bAR activates G+ by using the ~:-F region pres- 
ently identified in the C-terminal end of 13 (Fig. 3). 
Furthermore, because the region that can activate Gi/Go 
potently and selectively has been found in cz~AR, it is 
reasonable to assume that the N-terminal sequence of 
I~ that weakly and non-selectively activates Gi/Go/G, 
may specify the region that potently activates ome 
other G protein. 
It has been suggested that ~h-adrenergic stimulation 
of phospholipase A.~ in platelets is desensitized by pro- 
tein kinase C activation [26]. Since the peptide g,.-F 
sequence contains a possible phosphorylation site for 
protein kinase C, it is an interesting question whether 
peptide %-F loses the Gractivating function when it is 
s¢lectlve Gs-activator RITQIAKRRTR selsctive GhtGo-aeli'tator 
low-potency non.sol~Uve 
G protein.activator 
Fig, 3. Integrated scheme illustratin~ the cytoplasmic functional do- 
mains in (x:AR. This figure illustrates the location of three functional 
domains in ¢z:AR and their significance. We [17] have identified the 
second intracellular loop region RYWSITQAIEYNLKRTPR that 
specifically activates G,, and the N-tem~inal region of the third intra- 
cellular loop RITQIAKRRTR that a¢tivates G,, G+ and Go with low 
potencies. In the present study, the C-terminal ~gion of the third 
intracellular loop KASRWRGRQNREKRFTF has been found to be 
highly potent in activating G~ and Go. The configuration of ~:AR is 
based on ref. 21. 
31 
Volume 311, number 1 FEBS LETTERS October 1992 
phosphorylated by purified protein kinase C. We previ- 
ously reported a similar phosphorylation.mediated r g- 
ulation of the active peptide in a G-coupled receptor 
[22]. The G:activator region in I) offl_~AR is subject to 
protein kinase A-dependent phosphorylation, resulting 
in a drastic reduction in the O:coupling ability and 
potentiation of the G:activating function. The present 
study may be important in this regard as well, since 
investigators can focus on the limited region of residues 
356-372 when they investigate the cellular mechanism 
that modulates the function of ~:AR. 
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